comparemela.com

Latest Breaking News On - ஆரோக்கியம் புற்றுநோய் மையம் - Page 7 : comparemela.com

IMMray PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network

IMMray PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network LUND, Sweden, April 16, 2021 /PRNewswire/ Immunovia s bloodtest IMMray PanCan-d was mentioned in the seminar The latest in early detection for pancreatic cancer arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021. Dr. Rosalie Sears, professor in the department of molecular and medical genetics at Oregon Health and Science University, expressed her enthusiasm for Immunovias bloodtest and the test performance. She was especially impressed by the fact that a non-invasive bloodtest can be used to detect early stages I and II of pancreatic cancer which is crucial for improving treatment outcomes in pancreatic cancer care.

IMMray™ PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network

Share this article LUND, Sweden, April 16, 2021 /PRNewswire/  Immunovia s bloodtest IMMray™ PanCan-d was mentioned in the seminar The latest in early detection for pancreatic cancer arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021. Dr. Rosalie Sears, professor in the department of molecular and medical genetics at Oregon Health and Science University, expressed her enthusiasm for Immunovias bloodtest and the test performance. She was especially impressed by the fact that a non-invasive bloodtest can be used to detect early stages I and II of pancreatic cancer which is crucial for improving treatment outcomes in pancreatic cancer care. Oregon Health and Science University is one out of 23 centers participating in Immunovia s study PanFAM-1, one of the largest prospective studies to date focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC).

Immunovia publishes the annual report for the financial year 2020

Immunovia publishes the annual report for the financial year 2020 News provided by Share this article LUND, Sweden, March 12, 2021 /PRNewswire/ Immunovia has today published the annual report for 2020. It is available on Immunovia s website . After many years of intensive preparation, Immunovia is close to a commercial breakthrough with the launch of our blood test for early detection of pancreatic cancer - IMMray™ PanCan-d - in the first quarter of 2021. Thus, Immunovia will be the first company in the world to launch a test that, by virtue of its early detection capabilities, can provide improved care and survival of pancreatic cancer patients, said Patrik Dahlen, CEO Immunovia.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.